glp-1 news nov 2025 Shortage = Over 2025 dominates for GLP-1 trial
Description
According to the American Diabetes Association (ADA), these are among the two first-line therapies for T2D patients at risk for ischemic heart disease or other atherosclerotic cardiovascular disease
Even if youre temporarily deferred, your contribution could still be possible at a later date
Congressional Record Discussion on TRICARE Coverage of Obesity Treatments Provides background on the legislative framework that guides TRICAREs coverage limitations for weight-loss medications
Available from: 177
They are eating incorrectly
The fact that patients in this trial continued to lose weight after gastrointestinal adverse effects had subsided suggests that these effects were not the cause of weight loss
